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ABSTRACT 
 
Aims 
Periodontal diseases negatively affect implant osseointegration. Perturbations in 
non-neuronal cholinergic signaling mechanisms are associated with periodontitis; 
however, their role in generalized aggressive periodontitis (GAgP) is unknown. The 
aim of this prospective case-control study was to determine the relationship between 
non-neuronal cholinergic signaling mechanisms, Secreted Ly-6/uPAR-related 
protein-1 (SLURP-1), Interleukin-17 (IL-17) family cytokines and healing of dental 
implants in health and GAgP. 
 
Materials and Methods 
Thirteen GAgP patients and seven periodontally healthy individuals (PH) were 
recruited. Peri-implant crevicular fluid (PICF) was obtained at baseline and 1-month 
post-placement. Acetylcholine (ACh) levels and cholinesterase activity were 
determined biochemically. SLURP-1, IL-17A and IL-17E levels were determined by 
ELISA. Marginal bone loss (MBL) at 1- and 6-month(s) post-placement was 
determined radiographically. 
 
Results 
The concentration of ACh, cholinesterase activity and IL-17A levels were elevated in 
PICF of patients with GAgP compared to PH individuals at baseline and 1-month 
post-placement. The concentration of ACh and cholinesterase activity levels in PICF 
correlated with levels of IL-17A and MBL around implants 1-month post-placement in 
patients with GAgP. 
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Conclusions 
Non-neuronal cholinergic mechanisms may play a role in the aetiopathogenesis of 
GAgP and may directly or indirectly, through modulation of IL-17A, influence early 
implant osseointegration and potential long-term implant survival. 
 
CLINICAL RELEVANCE 
 
Scientific Rationale 
Perturbations in cholinergic signaling mechanisms correlate with alveolar bone loss 
in periodontitis. The role of cholinergic signaling in healing of implants placed in 
GAgP patients is unknown. 
 
Principal Findings 
Acetylcholine levels, IL-17A levels and cholinesterase activity were elevated in PICF 
of patients with generalized aggressive periodontitis. Acetylcholine levels and 
cholinesterase activity in PICF of patients with GAgP correlated with IL-17A levels 
and marginal bone loss around implants 1-month post-placement. 
 
Practical Implications 
The data demonstrates the need for further study into the role of cholinergic 
mechanisms and IL-17A in modulating early osseointegration events in patients with 
GAgP.  
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INTRODUCTION 
Dental implants are a widely used treatment option for both fully and partially 
edentulous individuals. Periodontally compromised patients also benefit from dental 
implants for replacement of their missing teeth. Implant survival ratio is no longer 
considered as a challenge. Indeed, contemporary dental implants have on average a 
95 - 100% rate of 5 - 10-year survival depending on the implant design (Buser et al. 
2012, Karl and Albrektsson. 2017, Dong Mei et al. 2018). However, it is well 
documented that over this time, approximately 38% of dental implants exhibit 
complications (Pjetursson et al., 2007); and susceptibility to periodontal diseases is 
one of the major factors that influence long-term implant survival (Roccuzzo et al., 
2014, Roccuzzo et al., 2010, Gatti et al., 2008).  
There are a limited number of studies that have specifically evaluated survival rates 
of implants in patients having the clinical diagnosis of GAgP (Swierkot et al., 2012, 
Mengel et al., 2007). Anitua et al. (2008) reported that 69% of patients with implant 
failure presented with a history of chronic periodontitis or GAgP. Furthermore, 
patients with GAgP showed an implant survival rate of just 83.3% and significantly 
greater marginal bone loss than their periodontally healthy counter parts (Mengel et 
al., 2007). Patients with GAgP were 5 times more likely to experience implant failure 
and 14 times more likely to experience peri-implantitis than periodontally healthy 
individuals (Swierkot et al., 2012). Moreover, initial clinical periodontal diagnosis (e.g. 
GAgP vs. chronic periodontitis) has been suggested to effect implant failure rate 
(Monje et al., 2014). One reason may be the higher marginal bone loss observed in 
patients with GAgP during the first year after implant placement (Mengel et al., 
2007). However, the exact mechanisms of higher marginal bone loss around dental 
implants in patients with GAgP have yet to be clarified. 
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Cholinergic mechanisms exist in the periodontium and acetylcholine (ACh) has been 
found to play important roles in both periodontal health and disease (Nguyen et al., 
2000, Arredondo et al., 2003, Zoheir et al., 2012). ACh is synthesised by cells of the 
periodontium expressing choline acetyltransferase (ChAT) from acetyl COA and 
choline (Wessler and Kirkpatrick, 2008). However, an important determinant of levels 
of ACh in biofluids are the levels of acetylcholinesterase (AChE) and 
butyrylcholinesterase (BCHE) activity (Pope and Brimijoin, 2018).  
 
In health, there is a delicate balance between ACh synthesis and degradation (Nizri 
et al., 2007). Perturbations in this balance play roles in the aetiopathogenesis of 
inflammatory diseases (Fujii et al., 2017, Hoover, 2017). ACh acts through 2 major 
receptor subtypes; nicotinic (nAChR) and muscarinic receptors (mAChR) (Wessler 
and Kirkpatrick, 2008). ACh has anti-inflammatory properties through activation of 
ACh receptors; in particular the alpha 7 nicotinic receptor (α7nAChR) (Rosas-Ballina 
and Tracey, 2009). However, ACh, via other cholinergic receptor subtypes, can also 
have proinflammatory properties (Kistemaker et al., 2012). Therefore, cholinergic 
mechanisms may ‘fine tune’ the immune response and promote effective clearance 
of pathogenic threats whilst limiting bystander tissue damage (Rajendran et al., 
2015).  
 
Secreted Ly-6/uPAR-related protein 1 (SLURP-1) is a member of the Ly6/uPAR 
family of proteins and shares some structural homology with nAChR agonists 
(Vasilyeva et al., 2017). SLURP‐1 can act as allosteric antagonist of the α7nAChR 
but has also been demonstrated to activate metabotropic-signalling pathways 
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(Lyukmanova et al., 2016). SLURP-1 is secreted at mucosal sites and has also been 
shown to have both immunomodulatory (Moriwaki et al., 2007) and antimicrobial 
properties (Moriwaki et al., 2015). In addition, SLURP-1 has been found to inhibit 
proliferation of oral keratinocytes (Lyukmanova et al., 2016). However, the exact 
roles of SLURP-1 in oral infections have still to be delineated.  
 
Levels of IL-17 family cytokines, particularly elevated levels of IL-17A and 
perturbations in the IL-17A:IL-17E ratio, in gingival crevicular fluid (GCF) have been 
shown to be associated with bone loss in periodontal diseases (Awang et al 2014). 
Recently, clinical evidence for an association between biofluid levels of ACh, 
esterase activity and periodontal diseases have also been established (Apatzidou et 
al., 2018). Furthermore, there is evidence to suggest that cholinergic mechanisms 
can modulate bone metabolism and turnover (En-Nosse et al., 2009, Kauschke et 
al., 2015, Haupt et al., 2015, Ternes et al., 2015). However, no studies have 
investigated the role of cholinergic mechanisms, SLURP-1 and IL-17 family 
cytokines in implant placement outcomes. The aim of this research therefore was to 
determine the relationship between cholinergic signaling mechanisms, inflammation 
and the early healing phases of dental implants in health and GAgP. 
 
MATERIALS AND METHODS 
Study population 
Twenty patients (13 GAgP patients and 7 periodontally healthy individuals) were 
recruited for this prospective, case-control study between October 2016 - May 2018 
at the Department of Periodontology, School of Dentistry, Ege University. The study 
was conducted in full accordance with ethical principles, including the World Medical 
A
cc
ep
te
d
 A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
Association’s Declaration of Helsinki, as revised in 2000. The study protocol was 
approved by the Ethics Committee of Ege University, İzmir, Turkey (Protocol 
number; 16-10/2). Written informed consent was received from each patient before 
enrolment in the study. Detailed medical and dental histories were obtained from all 
participants and clinical and radiographic examinations were performed. Eligible 
patients had a clinical diagnosis of GAgP (Armitage, 1999). According to the new 
classification system, there is no longer differentiation between generalized chronic 
or aggressive periodontitis. Based on this new classification the patients recruited for 
the present study are in stage 3 (Papapanou et al., 2018). All patients were in the 
maintenance phase following initial treatment for at least one year with full-mouth 
plaque and bleeding scores <20%, sufficient bone volume for standard sized 
implants and no extractions in the edentulous sites in the last year. Individuals were 
excluded if they had history of systemic diseases, were pregnant, had physical 
and/or psychiatric disorders which hinder optimum plaque control and used 
antibiotics and/or anti-inflammatory drugs within the last six months. Periodontally 
healthy individuals (Offenbacher et al., 2008) in need of implant placement made up 
the control group. Smoking status was assigned following the criteria described by 
Schwartz-Arad et al, (2002). 
 
Surgical procedure 
All implants (3.8 mm in diameter & 7 or 9 mm in length, Isy, Camlog, Basel, 
Switzerland) were placed in the left or right sides of the maxilla/mandible under local 
anesthesia with a minimal flap reflection to minimize trauma to the gingival papillae. 
One stage surgery was performed, and gingiva formers were placed on a pre-
mounted implant base. The flaps were closed with single interrupted sutures using a 
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5-0 propylene suturing material. After a healing period of 12 weeks, the prosthetic 
process was initiated. No grafting of soft or hard tissues was performed and no 
medication was prescribed for any patient. All implants were placed by the same 
periodontist (PM). The sutures were removed 10 days post-operatively. At each 
recall session, the patients were re-motivated and re-instructed in effective oral 
hygiene to maintain whole mouth plaque and bleeding scores < 20%; as assessed 
by visual examination. 
 
 
Prosthetic procedures 
The healing caps were removed after the osseointegration period. Conventional 
impression taking was performed with a polyether impression material (Impregum 
PentaDuoSoft H, 3M, Seefeld, Germany). Titanium bases (Ti-base for Isy, Camlog) 
compatible with the implant diameter were placed on the cast models and optical 
impressions were made (in-Eos X5, Sirona). The abutment crowns were designed 
and milled (Cerec MCXL, Sirona) out of lithium-disilicate glass-ceramic blocks 
(e.max CAD, IvoclarVivadent, Schaan, Liechtenstein). After crystallization, the 
crowns were adhesively luted to titanium bases by a self-adhesive resin cement 
(Multilink Hybrid Abutment Cement, IvoclarVivadent). After removing excess cement, 
the abutments were sterilized in an autoclave for 15 min at 121°C. A 30-Ncm torque 
was applied on the implant and the screw hole was restored with a composite resin 
to further isolate the adhesive area from the oral environment. All prosthetic 
procedures were performed by the same prosthodontist (EÇ). The patients were 
informed and educated on maintaining an optimal oral hygiene regimen. 
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Radiographic analysis 
Marginal bone level (MBL) was evaluated on the standardized periapical radiographs 
taken using a film holder (Super-Bite film-holding system [Kerr Corporation, Orange, 
CA, USA]) at 10-days, 1-month and 6-months post-surgery by using the long cone 
paralleling technique. Care was taken to parallel the alignment of the X-ray film in the 
film holder to the long axis of the implants. Images were taken with an intra oral 
radiation unit using an acylindrical tube head, 2.5mm aluminium filtration and a focal 
spot distance of 200 mm. The exposure settings were 70 kV and 1.12 mAs.  Images 
were transferred to the computer by a photostimulatable phosphor plate scanner 
(Digora Optime, Soredex, Milwaukee Wisconsin). Implant lengths were used as the 
reference for measurements on each image. MBL was calculated at the mesial and 
distal implant surfaces by measuring the distance between the most coronal point of 
the implant and the most coronal radiographic bone-implant contact with the image 
analysis software program (ImageJ, for Windows, NIH, Bethesda, MD). Bone loss at 
1-month and 6-months was calculated by subtracting the MBL at these time-points 
from the MBL at baseline (10-days after implant placement). Mean values from 
triplicate measurements were calculated. All measurements were performed by a 
single calibrated examiner (PM).  
 
Biofluid sampling 
Peri-implant crevicular fluid (PICF) samples were obtained at baseline and at 1-
month after implant placement. PICF was collected using paperstrips (Periopaper; 
ProFlow, Inc., Amityville, NY) by inserting the strip 1 mm into the crevice and leaving 
in place for 30 sec. Care was taken to avoid mechanical injury; samples with visual 
blood contamination were discarded. The PICF volume absorbed on to each paper 
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strip was determined by a specific electronic impedance device (Periotron 8000, 
ProFlow, Inc., Amityville, NY, USA) and the strip was placed in one sterile 
polypropylene tube. Samples were immediately frozen and stored at -40°C until the 
laboratory analysis. Readings from the Periotron 8000 were converted to actual 
volumes (µl) by reference to the standard curve.  
 
Quantification of Acetylcholine levels and cholinesterase activity in PICF 
samples 
ACh levels were quantified using the Acetylcholine Assay Kit in fluorometric mode as 
per manufacturers instructions (Abcam, Cambridge, UK). Assay plates were 
analyzed on a microplate reader (BMG-Labtech, Ortenberg, Germany) in 
fluorometric assay mode at Ex/Em = 535/587 nm.  
 
AChE and BChE activity levels was determined using a modified version of the 
biochemical assay developed by Naik et al (Naik et al., 2013) as previously 
described  (Apatzidou et al., 2018). 
 
Quantification of IL17A, IL17E and SLURP-1 levels in PICF samples 
Levels of IL-17A and IL-17E were determined using commercially available ELISA 
kits (Peprotech, UK); as previously described (Apatzidou et al., 2018). Levels of 
SLURP-1 were determined using an in-house ELISA. In brief, microtitre plates were 
coated with 3 µg/ml of rabbit polyclonal anti-SLURP-1 capture antibody (ABNOVA, 
Oxford, UK). The plates were then blocked with 1% BSA. A standard curve was 
developed using a LYNX1 (SLURP-1) overexpressed lysate (Origene, Rockville, 
USA) with an assay standard range of 3.13 - 400 pg/mL. One hundred µl of prepared 
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standards or sample were assayed in triplicate. Detection was carried using 2 µg/ml 
of mouse monoclonal anti-SLURP-1 detection antibody (ABNOVA, Oxford, UK) and 
a 1/5000 dilution of biotin labelled anti-mouse IgG (SIGMA, Poole, UK). Colour 
development was performed using a 1/2000 dilution of Streptavidin HRP (Peprotech, 
London, UK) and TMB substrate (Insight Biotechnology, Wembley, UK). The reaction 
was stopped with 1 M HCl and the absorbance was measured at 450 nm with 
wavelength correction set at 650 nm using a microplate reader (FLUOstar Omega; 
BMG Labtech, Germany). The limits of detection for each assay were determined as 
two mean standard deviations higher than the mean baseline from six replicate 
standard curves: IL-17A = 1.9 pg/ml; IL-17E = 3.8 pg/ml and SLURP-1 = 3.1 pg/ml. 
 
Statistical analysis  
Alpha was set to 5% and statistical power analysis was determined for independent 
sample parametric tests. To achieve 80% statistical power with an effect size of 1.5, 
average group sizes of n=8 would be required. For non-parametric tests average 
group sizes of n>9 would be necessary. However, with the same effect sizes, group 
sizes of n>7 would exceed 80% statistical power in dependent sample, non-
parametric statistical analyses.  
 
Cross-sectional analysis was performed on the participants comparing the 
measurements from implants of GAgP patients with implants from healthy individuals 
using the Mann-Whitney-U-test. Differences between measurements of biomarkers 
at baseline and 1-month were analyzed using the Wilcoxon rank test. The non-
parametric Kendal Tau correlation test was used to investigate relationships between 
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the measured parameters.  Furthermore, the relationship between MBL and 
biomarker levels or activity was investigated using a linear regression model.   
 
RESULTS  
 
Study population 
Table 1 shows the demographic parameters and clinical outcomes for the study 
population. The median ages of the periodontitis patients and the healthy controls 
were similar (35 and 34 years, respectively). There was no significant difference in 
the number of smokers or in the gender distribution between the groups. The 
distribution of implants in the maxilla and mandible was equal. Marginal bone loss 
was significantly greater around implants in the GAgP group at 1-month and 6-
months (p= 0.026 and p= 0.019, respectively) compared to the PH group. Marginal 
bone loss was increased in the GAgP patients at 6-months compared to 1-month (p= 
0.021). However, there was no significant difference in marginal bone loss between 
the measurements at 1-month and 6-months in the PH group (p>0.05).  
 
Concentrations of Acetylcholine and esterase activity in PICF  
ACh concentrations in PICF samples were significantly greater in the patients with 
GAgP than in the PH patients at baseline and 1-month (both p< 0.001). 
Concentrations of ACh were significantly higher at 1-month than at baseline in PH 
patients (p= 0.013) (Figure 1A). AChE activity was significantly greater in patients 
with GAgP than in PH patients at baseline and 1-month (both p< 0.001). AChE 
activity was significantly greater at 1-month than at baseline in both PH and GAgP 
groups (p=0.018 and p<0.001, respectively) (Figure 1B). BChE activity was 
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significantly greater in GAgP group than PH group at baseline and 1-month (both p< 
0.001). BChE activity was significantly lower at 1-month than at baseline in PH group 
(p= 0.012) (Figure 1C). 
 
Secreted Ly-6/uPAR-related protein-1, IL-17A and IL-17E levels in PICF  
At baseline SLURP-1 levels were significantly greater in patients with GAgP than in 
PH patients (p= 0.022). Levels of SLURP-1 were greater at 1-month compared to 
baseline in both PH and GAgP groups (p=0.001 and p<0.006, respectively) (Figure 
2A). At baseline and 1-month IL-17A levels were significantly greater in patients with 
GAgP than PH patients (both p<0.001). Furthermore, IL-17A concentrations were 
greater in patients with GAgP at 1-month compared to baseline (p<0.01) (Figure 2B). 
At baseline, IL-17E levels were significantly lower in patients with GAgP than PH 
patients (p=0.026). At 1-month IL-17E levels were higher than baseline in both PH 
patients (p=0.0425) and in patients with GAgP (p<0.001) (Figure 2C). The ratio of IL-
17A:IL-17E was higher in patients with GAgP than PH patients at both baseline and 
1-month (both p< 0.001) (Figure 2D). 
 
Correlations between biological parameters  
At baseline (Table 1A) ACh concentrations correlated with AChE activity, IL-17A 
levels and the IL-17A:IL-17E ratio (Tau= 0.389, p<0.001; Tau =0.363, p<0.001; Tau= 
0.395, p<0.001, respectively). AChE activity correlated with IL-17A levels, the IL-
17A:IL-17E ratio and SLURP-1 levels (Tau= 0.549, p<0.001; Tau= 0.435, p<0.001; 
Tau= 0.390, p= 0.001, respectively). BChE activity correlated negatively with IL-17E 
levels (Tau= -0.275, p=0.010). IL-17A levels correlated with SLURP-1 levels (Tau= 
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0.441, p<0.001). IL-17E levels correlated with SLURP-1 levels (Tau =0.364, 
p=0.001).  
 
At 1-month (Table 1B) ACh concentrations correlated with AChE activity, IL-17A 
levels, IL-17E levels, SLURP-1 levels and the IL-17A:IL-17E ratio (Tau= 0.674, 
p<0.001; Tau= 0.713, p<0.001; Tau= 0.507, p<0.001; Tau=0.584, p<0.001; 
Tau=0.535, p<0.001, respectively). AChE activity correlated with BChE activity, IL-
17A levels, IL-17E levels, SLURP-1 levels and the IL-17A:IL-17E ratio (Tau= 0.369, 
p=0.001; Tau= 0.729, p<0.001; Tau= 0.568, p<0.001; Tau=0.388, p=0.001; Tau= 
0.511, p<0.001, respectively). BChE activity correlated with IL-17A levels (Tau= -
0.280, p=0.011). IL-17A levels correlated with IL-17E levels, the IL-17A:IL-17E ratio 
and SLURP-1 levels (Tau= 0.448, p<0.001; Tau= 0.757, p<0.001 and Tau= 0.472, 
p<0.001, respectively). IL-17E levels and the IL-17A:IL-17E ratio correlated with 
SLURP-1 levels (Tau= 0.344, p=0.001 and Tau= 0.560, p<0.001, respectively). 
 
Correlations between biological parameters and clinical outcome 
 
There were statistically significant correlations between baseline ACh concentrations 
(Tau=0.573, p<0.001), AChE activity (Tau= 0.249, p=0.037), IL-17A levels (Tau= 
0.398, p=0.001) and the IL-17A:E ratio (Tau= 0.445, p<0.001) and MBL recorded at 
1-month. There were no statistically significant correlations between any of the 
biological parameters in PICF at 1-month with MBL at 1-month or 6-months. In a 
linear regression model using MBL as the determinant the only statistically significant 
correlations were between MBL at 1 month and baseline measurements of ACh and 
SLURP-1 (R=0.475, p<0.001; R=0.254, p= 0.046, respectively).  
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DISCUSSION 
Patients with periodontitis, or a history of periodontitis, exhibit more biological 
complications and a higher rate of implant loss than patients with a healthy 
periodontium (Roccuzzo et al., 2014, Roccuzzo et al., 2010, Gatti et al., 2008). 
Periodontitis can be classified as chronic or aggressive. The latter presents clinically 
with a rapid form of tissue destruction and is much less prevalent in the population 
(<1%). Although the relationship between chronic periodontitis and implant success 
rates has been extensively studied, to date, few studies have specifically evaluated 
survival rates and early osseointegration events around implants in patients with the 
clinical diagnosis of GAgP.  
 
In this study, we report for the first time that levels of ACh, SLURP-1 and both AChE 
and BChE activity were elevated in PICF samples of patients with GAgP compared 
to those with a healthy periodontium at both baseline (10 days after implant 
placement) and 1-month. A linear regression model where MBL was used as the 
determinant substantiated the finding as baseline ACh and SLURP-1 levels 
correlated with MBL at 1-month. Furthermore, non-parametric correlation analysis 
indicated that baseline ACh concentration and AChE activity levels correlated with 
MBL recorded at 1-month. This is in agreement with a previous study which 
demonstrated that ACh levels and esterase activity in saliva and gingival crevicular 
fluid correlated with alveolar bone loss in chronic periodontitis (Apatzidou et al., 
2018).   
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The relationship between esterase activity and bone metabolism has been 
investigated previously. Knock-out of AChE and BChE in mice had no major 
significant effects on bone parameters (Kauschke et al., 2015, Haupt et al., 2015). 
However, in AChE knock-out mice the number of osteoclasts per perimeter was 
significantly reduced in lumbar vertebrae (Kauschke et al., 2015) and in BChE 
knock-out mice a significant increase in relative osteoclast number was observed 
(Haupt et al., 2015). The role of ACh in bone metabolism remains unclear. Non-
neuronal cholinergic systems are present in both osteoclasts and osteoblasts and 
suggested to play a role in bone turnover (En-Nosse et al., 2009, Ternes et al., 
2015). Indeed, osteoblasts express both nicotinic (nAChRs) and muscarinic ACh 
receptors (mAChRs) and ACh has been shown to regulate their proliferation and 
differentiation (Sato et al., 2010). In contrast, ACh did not have any direct activity on 
osteoclasts in vitro (Ternes et al., 2015). However, in vivo, the alpha 7 nicotinic 
receptor (α7nAChR) on macrophages has been demonstrated to regulate bone 
turnover by inhibiting TNF-a expression and subsequently down regulating 
osteoblastogenesis and promoting osteoclast activity (Mito et al., 2017). In terms of 
SLURP-1, there is no direct evidence for a role in hard tissue homeostasis however, 
as an activator of the  α7nAChR it has been shown to indirectly regulate the ability of 
deciduous dental pulp stem cells DDPSCs to influence osteoclastogenesis and 
enhance resorption  (Wang et al., 2017). Therefore, the evidence suggests that 
cholinergic mechanisms can have both direct and indirect effects on bone 
metabolism; the latter through modulation of the host immune response. 
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In this study, levels of IL-17A and IL-17E, as well as the IL-17A:IL-17E ratio are all 
elevated in PICF of patients with GAgP at baseline. Furthermore, levels of IL-17A 
and the IL-17A:IL-17E ratio are elevated in PICF of patients with GAgP compared to 
those with a healthy periodontium at 1-month. Indeed, there were statistically 
significant correlations between baseline IL-17A levels and the IL-17A:E ratio with 
MBL recorded at 1-month. In addition, there are moderate to strong statistically 
significant correlations between ACh concentration and AChE activity with IL-17A 
levels in PICF at baseline and 1 month.  
 
The role of IL-17A in the pathogenesis of periodontal diseases has received 
considerable attention. IL-17A has been demonstrated to have potent pro-
osteoclastogenic effects and be a key driver of alveolar bone loss in periodontal 
diseases (Zenobia and Hajishengallis, 2015). Gingival crevicular fluid and saliva 
concentrations of ACh have previously been found to significantly correlate with 
levels of IL-17A in patients with periodontal disease (Apatzidou et al., 2018). Indeed, 
previous studies have suggested that there may be links between cholinergic 
systems and expression of IL-17A in mucosal tissues. The existence of ChAT+ Th17 
cells has been reported in the gut and this subpopulation of T cells has been 
demonstrated to release ACh, IL-17A, IL-22 and IFNγ in response to activation by 
primed dendritic cells (Dhawan et al., 2016). In addition, IL-17A has been 
demonstrated to induce the synthesis and release of ACh in bronchial epithelial cells 
(Montalbano et al., 2016) and non-neuronal ACh has also been demonstrated to play 
a role in promoting the differentiation of Th17 cells (Profita et al., 2014). Therefore, 
the clinical findings described in this manuscript could be attributed to an interplay 
between cholinergic systems and IL-17A biology within the oral mucosa which may 
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influence early implant osseointegration in patients with GAgP. However, further 
clinical studies reinforced by both in vivo and in vitro research is required to confirm 
this hypothesis. 
 
Probing has limitations for assessment of implant success (Coli et al., 2017). In this 
study, MBL was determined on 2-D periapical radiographs. However, this may have 
caused underscoring of the real defect size as the image is a projection of the 
circumferential bone. An alternative approach could have been to use computed 
tomography (CT) as it can improve the resolution of anatomical structures allowing 
more accurate measurement. However, CT is currently not capable of accurately 
evaluating the implant circumferential bone level as it cannot accurately determine 
bone thickness. Moreover, it exposes the patient to a higher radiation dose than 
conventional 2-D imaging (De Bruyn et al., 2013). Therefore, radiographic evaluation 
continues to be the preferred method for evaluating implant health based on MBL 
(Cassetta et al., 2018).  
 
A limitation of this study was the fact that smoking was not considered as an 
exclusion factor since one-third of the Turkish population >15 years are smokers 
(Ozer et al., 2018). Smoking impacts both cholinergic systems (Wessler et al., 2003, 
Wessler and Kirkpatrick, 2008) and IL-17 immunity (Qiu et al., 2017). In this study, 
there was no statistical difference between the smoking status of the patient cohorts. 
However, for future studies it would be more pertinent to recruit non-smoker patient 
cohorts if feasible.   
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Within the limits of the present study, it may be concluded that the GAgP has a 
significant impact on early healing phases in implant therapy which are associated 
with perturbations in cholinergic signalling mechanisms within the oral mucosa. 
These perturbations may have direct effects on bone metabolism via the presence of 
muscarinic and nicotinic receptors on osteoclasts and osteoblasts. In addition, the 
study provides more evidence for a relationship between cholinergic signalling and 
IL-17A which may demonstrate an indirect relationship between cholinergic 
signalling and early osseointegration events in implant placement. The current 
investigation therefore may provide a primer to further studies to investigate the  
therapeutic potential of targeting non-neuronal cholinergic mechanisms to treat peri-
implantitis in patients with GAgP. 
 
Source of Funding  
The study was self-funded by the authors and their institutions, but all implants used 
in this study were kindly provided by Oral Reconstruction Foundation, Basel, 
Switzerland.  
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FIGURE LEGENDS 
 
Figure 1. Box and whisker plots show the median and quartiles of the peri-implant 
crevicular fluid levels of (A) ACh, (B) AChE activity and (C) BChE activity around 
implants placed in the periodontium of healthy persons (Healthy implant) and 
patients with GAgP (GAgP implant) at baseline and 1-month post-surgery. * = 
P<0.05, ** = P<0.01 and *** P<0.001. 
 
Figure 2:  Box and whisker plots show the median and quartiles of the peri-implant 
crevicular fluid levels of (A) SLURP-1, (B) IL-17A, (C) IL-17E and (D) the IL-17A:IL-
17E ratio around implants placed in the periodontium of healthy persons (Healthy 
implant) and patients with GAgP (GAgP implant) at baseline and 1-month post-
surgery. * = P<0.05, ** = P<0.01 and *** P<0.001. 
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Male/ Female 
Smoker/ 
Non-smoker Age (years) 
Marginal bone 
loss  
(1 month; mm) 
Marginal bone 
loss  
(6 months; mm) 
Healthy 
implants 
3 / 4 3 / 4 
34.0 
(33.0-35.5) 
33.88 ± 3.99 
 
0.00 
(0.00-0.00) 
0.00 ± 0.00 
0.00 
(0.00-0.00) 
0.00 ± 0.00 
GAgP 
implants 
8 / 5 7 / 6 
35.0 
(33.0-38.0) 
34.69 ± 4.63 
0.00† 
(0.00-0.16) 
0.29 ± 0.63 
0.001†‡ 
(0.00-0.65) 
0.33 ± 0.48 
 
For age and bone loss the data shown represents the median (interquartile range) 
and mean ± standard deviation. †Significantly different from healthy group. 
‡Significantly different from 1 month value.  
 
  
A
cc
ep
te
d
 A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
Kendal-Tau correlations between biomarkers in PICF at baseline and 1-month post 
implant placement. ** Correlation is significant at the 0.01 level (2-tailed).* 
Correlation is significant at the 0.05 level (2-tailed). 
 
A 
         AChE BChE IL-17A IL-17E IL17A:IL17E SLURP-1 
ACh Tau=  0.389** 0.122 0.363** -0.09 0.395** 0.12 
 
p= <0.001 0.264 0.001 0.407 <0.001 0.269 
AChE Tau=  
 
0.142 0.549** -0.001 0.435** 0.390** 
 
p= 
 
0.187 <0.001 0.992 <0.001 <0.001 
BChE Tau=  
  
0.066 -0.275* 0.148 -0.045 
 
p= 
 
 
0.541 0.010 0.169 0.674 
IL-17A Tau=  
   
0.074 0.706** 0.441** 
 
p= 
  
 
0.486 <0.001 <0.001 
IL-17E Tau=  
    
-0.219* 0.364** 
 
p= 
   
 
0.040 0.001 
IL-17A:IL-17E Tau=  
     
0.189 
 
p= 
    
 
0.078 
B              
    AChE BChE IL-17A IL-17E IL-17A:IL-17E SLURP-1 
ACh Tau=  0.674** 0.189 0.713** 0.507** 0.535** 0.584** 
 
p= <0.001 0.084 <0.001 <0.001 <0.001 <0.001 
AChE Tau=  
 
0.369** 0.729** 0.568** 0.511** 0.388** 
 
p= 
 
0.001 <0.001 <0.001 <0.001 <0.001 
BChE Tau=  
  
0.280* 0.147 0.143 -0.029 
 
p= 
 
 
0.011 0.18 0.192 0.794 
IL-17A Tau=  
   
0.448** 0.757** 0.472** 
 
p= 
  
 
<0.001 <0.001 <0.001 
IL-17E Tau=  
    
0.205 0.560** 
 
p= 
   
 
0.055 <0.001 
IL-17A:IL-17E Tau=  
     
0.344** 
 
p= 
    
 
0.001 
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